Table 3 Induction of peptide-specific CTLs from the PBMCs of HLA-A11, -A31, and -A33 cancer patients

From: Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles

 

Peptide

 

Lck 90–99

Lck 449–458

Lck 450–458

Lck 452–461

EBV

TRP-2

HIV

Patient

IFN- γ (pg ml−1)

HLA-A11

 1

10

—

1

—

443

8

—

 2

40

15

—

54

3

36

—

 3

150

57

37

—

—

2

—

 4

57

9

30

—

2

28

—

 5

—

8

—

—

1

2

—

 6

60

116

44

34

1000

—

41

 7

87

2

232

133

583

140

—

 

5/7

2/7

4/7

3/7

3/7

3/7

1/7

HLA-A31

 8

15

6

—

26

11

4

—

 9

22

17

72

15

43

17

—

 10

34

98

23

30

32

40

—

 11

127

34

341

11

40

89

—

 12

299

96

118

31

12

—

—

 

3/5

3/5

4/5

1/5

3/5

2/5

0/5

HLA-A33

 13

151

55

28

13

48

19

—

 14

14

—

24

—

207

2

—

 15

61

60

105

15

39

157

—

 16

9

100

16

26

—

19

—

 17

3

6

—

—

67

20

—

 

2/5

3/5

3/5

1/5

3/5

1/5

0/5

Positive/total

10/17

8/17

11/17

5/17

9/17

6/17

1/17

  1. CTL=cytotoxic T lymphocyte; HLA=human leukocyte antigen; IFN-γ=interferon-γ; PBMC=peripheral blood mononuclear cell.
  2. The PBMCs from HLA-A11, -A31, and -A33 cancer patients were stimulated in vitro with the indicated Lck peptides.
  3. On day 14, the cultured PBMCs were tested for their reactivity to C1R-A11, -A31, or -A33 cells, which were pre-pulsed with a corresponding peptide or the HIV peptide. The values represent the results of positive wells among four wells, and the background IFN-γ production in response to the HIV peptide was subtracted. Significant values (P<0.05 by two-tailed Student's t-test) are shown in bold.
Back to article page